Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Sanofi Pasteur announces new quadrivalent influenza vaccine Phase III pediatric data

Sanofi Pasteur, the vaccines division of Sanofi, announced today new Phase III data for its investigational quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age.

2 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

2 May 2012

Allergies may provide benefit by keeping away noxious environmental toxins

Yale researchers suggested Wednesday that allergies may be an outgrowth of the protective mechanism of the body to protect itself from noxious substances in the environment.

26 Apr 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

21 Apr 2012

Purdue Pharma launches Intermezzo for middle-of-the-night insomnia

Purdue Pharma L.P. announced today that Intermezzo (zolpidem tartrate) sublingual tablet CIV is now available in 1.75 mg and 3.5 mg dosage strengths by prescription in retail pharmacies nationwide.

6 Apr 2012

FAAN plays a crucial role in supporting peanut allergy study

Why do some children develop a peanut allergy and others don't? Researchers trying to answer this crucial question in order to learn how to prevent this life-threatening food allergy believe that being exposed to peanuts through skin early in life could be a determining factor.

4 Apr 2012

Simple and accurate test for peanut allergy

The Murdoch Children’s Research Institute and University of Melbourne researchers discovered a two-pronged blood test will confirm peanut allergies instead of putting children through risky oral food challenge tests.

21 Mar 2012

New way to accurately test for peanut allergy

Researchers from Murdoch Childrens Research Institute and the University of Melbourne have identified a new way to accurately test for peanut allergy.

21 Mar 2012

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2011. As of December 31, 2011, the company's cash, cash equivalents and investments totaled approximately $230 million.

5 Mar 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012

Dyax fourth quarter total revenues decrease to $8.5 million

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2011.

22 Feb 2012

Pfizer, Mylan enter settlement agreement to resolve e-cue patent litigation

Mylan Inc. and Pfizer Inc. today announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Intelliject and Sanofi-Aventis that will resolve pending patent litigation related to Intelliject's 505(b)(2) new drug application (NDA) for its epinephrine auto-injector known as e-cue, which will be manufactured and marketed by Sanofi-Aventis.

16 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

30 Jan 2012